Wedoany.com Report-Dec.30, Osaikang announced that its subsidiary Jiangsu Osaikang Pharmaceutical Co., Ltd. has entered into a license agreement with Hangzhou Adlai Nortye Biopharmaceutical Co., Ltd. According to the agreement, Osaikang Pharma will obtain exclusive rights for the development, production, and commercialization of the in-progress Type 1 innovative drug AN9025 project from Adlai Nortye within the licensed territory. Osaikang Pharma will pay Adlai Nortye milestone payments associated with various stages of product development, registration, and market launch, totaling no more than 470 million RMB. Osaikang Pharma will also pay Adlai Nortye sales milestone payments upon the achievement of certain sales targets, totaling no more than 1.128 billion RMB. The AN9025 project is a novel oral pan-RAS inhibitor developed by Adlai Nortye, intended for the treatment of RAS-mutant solid tumors. Preclinical data shows that AN9025 effectively inhibits multiple RAS mutations and has demonstrated significant and durable anti-tumor efficacy across various models, including lung cancer, pancreatic cancer, and colorectal cancer.